SRR8518398
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- G2M_CHECKPOINT+0.510
- MYC_TARGETS_V1+0.420
- MYC_TARGETS_V2+0.400
- MITOTIC_SPINDLE+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- HEDGEHOG_SIGNALING+0.280
- SPERMATOGENESIS+0.260
- MYOGENESIS+0.250
- DNA_REPAIR+0.220
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.390
- ADIPOGENESIS-0.330
- APICAL_SURFACE-0.300
- INTERFERON_GAMMA_RESPONSE-0.290
- PROTEIN_SECRETION-0.290
- FATTY_ACID_METABOLISM-0.270
- IL2_STAT5_SIGNALING-0.260
- IL6_JAK_STAT3_SIGNALING-0.260
- BILE_ACID_METABOLISM-0.250
- COMPLEMENT-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313155 | — | E | 0.884 |
| 2 | MNG873 | — | — | 0.811 |
| 3 | SRR8613782 | — | E | 0.808 |
| 4 | SRR8518399 | — | E | 0.804 |
| 5 | TCGA-AR-A2LR-01A-12R-A18M-07 | — | E | 0.799 |
| 6 | TCGA-B6-A0I6-01A-11R-A034-07 | — | E | 0.797 |
| 7 | SRR10842373 | — | — | 0.770 |
| 8 | SRR8518421 | — | E | 0.768 |
| 9 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.765 |
| 10 | TCGA-77-8139-01A-11R-2247-07 | — | cohortSQ1 | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |